

## REFERENCES

1. <http://www.who.int/mediacentre/factsheets/fs297/en/>
2. American Cancer Society. Cancer Facts & Figures 2007. Atlanta: American Cancer Society; 2007
3. Data and statistic in Thailand  
[http://www.who.int/ncd\\_surveillance/infobase/web/InfoBasePolicyMaker/reports/ReporterFullView.aspx?id=5](http://www.who.int/ncd_surveillance/infobase/web/InfoBasePolicyMaker/reports/ReporterFullView.aspx?id=5)
4. <http://chiangmai.nso.go.th/>
5. Parkin DM, Bray F, Ferlay J, *et al.* Global cancer statistics, 2002. *CA Cancer J Clin* 55 (2): 74-108, 2005.
6. Jemal A, Siegel R, Ward E, *et al.* Cancer statistics, 2007. *CA Cancer J Clin* 57 (1): 43-66, 2007.
7. <http://www.si.mahidol.ac.th/department/Cancer/home/tmregistry.html>
8. Call KM, Glaser T, Ito CY, *et al.* Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell* 60 (3): 509-20, 1990.
9. Gessler M, Poustka A, Cavenee W, *et al.* Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. *Nature* 343 (6260): 774-8, 1990.
10. Armstrong JF, Pritchard-Jones K, Bickmore WA, *et al.* The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. *Mech Dev* 40 (1-2): 85-97, 1993.
11. Moore AW, Schedl A, McInnes L, *et al.* YAC transgenic analysis reveals Wilms' tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb. *Mech Dev* 79 (1-2): 169-84, 1998.
12. Moore AW, McInnes L, Kreidberg J, *et al.* YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. *Development* 126 (9): 1845-57, 1999

13. Graham K, Li W, Williams BR, *et al.* Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells. *Gene Expr* 13 (1): 1-14, 2006.
14. Phelan SA, Lindberg C, Call KM. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. *Cell Growth Differ* 5 (6): 677-86, 1994.
15. Nakanishi Y, Oinuma T, Sano M, *et al.* Coexpression of an unusual form of the EWS-WT1 fusion transcript and interleukin 2/15 receptor betamRNA in a desmoplastic small round cell tumour. *J Clin Pathol* 59 (10): 1108-10, 2006.
16. Pritchard-Jones K, King-Underwood L. The Wilms tumour gene WT1 in leukaemia. *Leuk Lymphoma* 27 (3-4): 207-20, 1997.
17. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. *Blood* 87 (6): 2171-9, 1996.
18. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. *Blood* 91 (8): 2961-8, 1998.
19. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. *Int J Hematol* 73 (2): 177-87, 2001.
20. Bonetta L, Kuehn SE, Huang A, *et al.* Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts. *Science* 250 (4983): 994-7, 1990.
21. Rauscher FJ, 3rd, Morris JF, Tournay OE, *et al.* Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. *Science* 250 (4985): 1259-62, 1990.
22. Park S, Schalling M, Bernard A, *et al.* The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. *Nat Genet* 4 (4): 415-20, 1993.
23. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. *Leukemia* 6 (5): 405-9, 1992.
24. Guo X, Xu S, Dong Z. [WT1 gene expression in leukemia patients and its correlation with prognosis and multidrug resistance]. *Zhonghua Xue Ye Xue Za Zhi* 20 (2): 69-72, 1999.

25. Nakatani K, Nakahata N, Arakawa T, *et al.* Inhibition of cyclooxygenase and prostaglandin E2 synthesis by gamma-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. *Biochem Pharmacol* 63 (1): 73-9, 2002.
26. Furukawa K, Shibusawa K, Chairungsrilerd N, *et al.* The mode of inhibitory action of alpha-mangostin, a novel inhibitor, on the sarcoplasmic reticulum Ca(2+)-pumping ATPase from rabbit skeletal muscle. *Jpn J Pharmacol* 71 (4): 337-40, 1996.
27. Okudaira C, Ikeda Y, Kondo S, *et al.* Inhibition of acidic sphingomyelinase by xanthone compounds isolated from *Garcinia speciosa*. *J Enzyme Inhib* 15 (2): 129-38, 2000.
28. Matsumoto K, Akao Y, Yi H, *et al.* Preferential target is mitochondria in alpha-mangostin-induced apoptosis in human leukemia HL60 cells. *Bioorg Med Chem* 12 (22): 5799-806, 2004.
29. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 61 (5): 759-67, 1990.
30. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 100 (1): 57-70, 2000.
31. Lumb R, Bastian I, Chew W, *et al.* Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2002: a report of the Australian Mycobacterium Reference Laboratory Network. *Commun Dis Intell* 27 (4): 459-65, 2003.
32. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. *J Natl Cancer Inst* 91 (22): 1922-32, 1999.
33. Peters G, Vousden KH (eds). *Oncogenes and tumor suppressors*. New York: IRL Press at Oxford University Press; 1997.
34. Block M, Jacobson LO, Bethard WF. Preleukemic acute human leukemia. *J Am Med Assoc* 152 (11): 1018-28, 1953.
35. Hart GD. Acute Leukemia Following Phenylbutazone Therapy. *Can Med Assoc J* 90: 449-50, 1964.
36. Weinstein AW, Weinstein ED. A chromosomal abnormality in acute myeloblastic leukemia. *N Engl J Med* 268: 253-5, 1963.

37. Woodliff HJ, Dougan L. Acute Leukaemia Associated with Phenylbutazone Treatment. *Br Med J* 1 (5385): 744-6, 1964.
38. Abbatt JD, Lea AJ. The incidence of leukaemia in ankylosing spondylitis treated with x-rays. *Lancet* 271 (6957): 1317-20, 1956.
39. Brill AB, Tomonaga M, Heyssel RM. Leukemia in man following exposure to ionizing radiation. A summary of the findings in Hiroshima and Nagasaki, and a comparison with other human experience. *Ann Intern Med* 56: 590-609, 1962.
40. Bennett JM, Catovsky D, Daniel MT, *et al.* Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. *Br J Haematol* 33 (4): 451-8, 1976.
41. Miller DR, Leikin S, Albo V, *et al.* Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukaemia (ALL). *Br J Haematol* 48 (2): 199-206, 1981.
42. Burns CP, Armitage JO, Frey AL, *et al.* Analysis of the presenting features of adult acute leukemia: the French-American-British classification. *Cancer* 47 (10): 2460-9, 1981.
43. Sen L, Borella L. Clinical importance of lymphoblasts with T markers in childhood acute leukemia. *N Engl J Med* 292 (16): 828-32, 1975.
44. Greaves MF, Brown G, Rapson NT, *et al.* Antisera to acute lymphoblastic leukemia cells. *Clin Immunol Immunopathol* 4 (1): 67-84, 1975.
45. Crist WM, Grossi CE, Pullen DJ, *et al.* Immunologic markers in childhood acute lymphocytic leukemia. *Semin Oncol* 12 (2): 105-21, 1985.
46. Greaves MF, Janossy G, Peto J, *et al.* Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. *Br J Haematol* 48 (2): 179-97, 1981.
47. Foon KA, Todd RF, 3rd. Immunologic classification of leukemia and lymphoma. *Blood* 68 (1): 1-31, 1986.
48. Korsmeyer SJ, Arnold A, Bakhshi A, *et al.* Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. *J Clin Invest* 71 (2): 301-13, 1983.

49. Ha K, Hozumi N, Hrincu A, *et al.* Lineage specific classification of leukaemia: results of the analysis of sixty cases of childhood leukaemia. *Br J Haematol* 61 (2): 237-49, 1985.
50. Tawa A, Hozumi N, Minden M, *et al.* Rearrangement of the T-cell receptor beta-chain gene in non-T-cell, non-B-cell acute lymphoblastic leukemia of childhood. *N Engl J Med* 313 (17): 1033-7, 1985.
51. Look AT, Melvin SL, Brown LK, *et al.* Quantitative variation of the common acute lymphoblastic leukemia antigen (gp100) on leukemic marrow blasts. *J Clin Invest* 73 (6): 1617-28, 1984.
52. Reinherz EL, Nadler LM, Sallan SE, *et al.* Subset derivation of T-cell acute lymphoblastic leukemia in man. *J Clin Invest* 64 (2): 392-7, 1979.
53. Thiel E, Rodt H, Huhn D, *et al.* Multimarker classification of acute lymphoblastic leukemia: evidence for further T subgroups and evaluation of their clinical significance. *Blood* 56 (5): 759-72, 1980.
54. Smith LJ, Curtis JE, Messner HA, *et al.* Lineage infidelity in acute leukemia. *Blood* 61 (6): 1138-45, 1983.
55. Pui CH, Dahl GV, Melvin S, *et al.* Acute leukaemia with mixed lymphoid and myeloid phenotype. *Br J Haematol* 56 (1): 121-30, 1984.
56. Sobol RE, Mick R, Royston I, *et al.* Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. *N Engl J Med* 316 (18): 1111-7, 1987.
57. Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. *Blood* 81 (9): 2237-51, 1993.
58. Hossfeld DK. Chromosomes in acute lymphocytic leukemia. *Cancer Genet Cytogenet* 26 (1): 59-64, 1987.
59. Croce CM. Chromosome translocations and human cancer. *Cancer Res* 46 (12 Pt 1): 6019-23, 1986.
60. Mirro J, Kitchingman G, Williams D, *et al.* Clinical and laboratory characteristics of acute leukemia with the 4;11 translocation. *Blood* 67 (3): 689-97, 1986.
61. Pui CH, Raimondi SC, Murphy SB, *et al.* An analysis of leukemic cell chromosomal features in infants. *Blood* 69 (5): 1289-93, 1987.

62. Ribeiro RC, Abromowitch M, Raimondi SC, *et al.* Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. *Blood* 70 (4): 948-53, 1987.
63. Maurer J, Janssen JW, Thiel E, *et al.* Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. *Lancet* 337 (8749): 1055-8, 1991.
64. Erikson J, Griffin CA, ar-Rushdi A, *et al.* Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia. *Proc Natl Acad Sci U S A* 83 (6): 1807-11, 1986.
65. Westbrook CA, Hooberman AL, Spino C, *et al.* Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). *Blood* 80 (12): 2983-90, 1992.
66. Melo JV, Gordon DE, Tuszynski A, *et al.* Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia. *Blood* 81 (10): 2488-91, 1993.
67. Look AT, Roberson PK, Williams DL, *et al.* Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. *Blood* 65 (5): 1079-86, 1985.
68. Pui CH, Williams DL, Roberson PK, *et al.* Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia. *J Clin Oncol* 6 (1): 56-61, 1988.
69. Nichols J, Nimer SD. Transcription factors, translocations, and leukemia. *Blood* 80 (12): 2953-63, 1992.
70. Drexler HG, Minowada J. The use of monoclonal antibodies for the identification and classification of acute myeloid leukemias. *Leuk Res* 10 (3): 279-90, 1986.
71. Hanson CA, Gajl-Peczalska KJ, Parkin JL, *et al.* Immunophenotyping of acute myeloid leukemia using monoclonal antibodies and the alkaline phosphatase-antialkaline phosphatase technique. *Blood* 70 (1): 83-9, 1987.
72. Keating MJ, Cork A, Broach Y, *et al.* Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. *Leuk Res* 11 (2): 119-33, 1987.

73. Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. Report of the Workshop held in Leuven, Belgium, September 15-17, 1986. Second MIC Cooperative Study Group. *Cancer Genet Cytogenet* 30 (1): 1-15, 1988.
74. Tivey H. The prognosis for survival in chronic granulocytic and lymphocytic leukemia. *Am J Roentgenol Radium Ther Nucl Med* 72 (1): 68-93, 1954.
75. Dameshek W. Chronic lymphocytic leukemia--an accumulative disease of immunologically incompetent lymphocytes. *Blood* 29 (4): Suppl:566-84, 1967.
76. Werner H, Idelman G, Rubinstein M, *et al.* A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. *Cancer Lett*, 2006.
77. Preud'homme JL, Seligmann M. Surface bound immunoglobulins as a cell marker in human lymphoproliferative diseases. *Blood* 40 (6): 777-94, 1972.
78. Salsano F, Froland SS, Natvig JB, *et al.* Same idiotype of B-lymphocyte membrane IgD and IgM. Formal evidence for monoclonality of chronic lymphocytic leukemia cells. *Scand J Immunol* 3 (6): 841-6, 1974.
79. Fu SM, Winchester RJ, Feizi T, *et al.* Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes. *Proc Natl Acad Sci U S A* 71 (11): 4487-90, 1974.
80. Schroer KR, Briles DE, Van Boxel JA, *et al.* Idiotypic uniformity of cell surface immunoglobulin in chronic lymphocytic leukemia. Evidence for monoclonal proliferation. *J Exp Med* 140 (5): 1416-20, 1974.
81. Fialkow PJ, Najfeld V, Reddy AL, *et al.* Chronic lymphocytic leukaemia: Clonal origin in a committed B-lymphocyte progenitor. *Lancet* 2 (8087): 444-6, 1978.
82. Rai KR, Sawitsky A, Cronkite EP, *et al.* Clinical staging of chronic lymphocytic leukemia. *Blood* 46 (2): 219-34, 1975.
83. Cronkite EP. An historical account of clinical investigations on chronic lymphocytic leukemia in the Medical Research Center, Brookhaven National Laboratory. *Blood Cells* 12 (2): 285-95, 1987.
84. Zahm SH, Weisenburger DD, Babbitt PA, *et al.* Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. *Am J Public Health* 82 (7): 990-7, 1992.

85. Inskip PD, Kleinerman RA, Stovall M, *et al.* Leukemia, lymphoma, and multiple myeloma after pelvic radiotherapy for benign disease. *Radiat Res* 135 (1): 108-24, 1993.
86. Hjelle B, Mills R, Swenson S, *et al.* Incidence of hairy cell leukemia, mycosis fungoides, and chronic lymphocytic leukemia in first known HTLV-II-endemic population. *J Infect Dis* 163 (3): 435-40, 1991.
87. Floderus B, Persson T, Stenlund C, *et al.* Occupational exposure to electromagnetic fields in relation to leukemia and brain tumors: a case-control study in Sweden. *Cancer Causes Control* 4 (5): 465-76, 1993.
88. Stone R. Polarized debate: EMFs and cancer. *Science* 258 (5089): 1724-5, 1992.
89. Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. *J Natl Cancer Inst* 27: 1013-35, 1961.
90. Tough IM, Court Brown WM, Baikie AG, *et al.* Cytogenetic studies in chronic myeloid leukaemia and acute leukaemia associated with monogolism. *Lancet* 1: 411-7, 1961.
91. Baikie AG, Court-Brown WM, Buckton KE, *et al.* A possible specific chromosome abnormality in human chronic myeloid leukaemia. *Nature* 188: 1165-6, 1960.
92. Caspersson T, Gahrton G, Lindsten J, *et al.* Identification of the Philadelphia chromosome as a number 22 by quinacrine mustard fluorescence analysis. *Exp Cell Res* 63 (1): 238-40, 1970.
93. Caspersson T, Zech L, Johansson C, *et al.* Identification of human chromosomes by DNA-binding fluorescent agents. *Chromosoma* 30 (2): 215-27, 1970.
94. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* 243 (5405): 290-3, 1973.
95. Bartram CR, de Klein A, Hagemeijer A, *et al.* Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. *Nature* 306 (5940): 277-80, 1983.
96. Faderl S, Talpaz M, Estrov Z, *et al.* The biology of chronic myeloid leukemia. *N Engl J Med* 341 (3): 164-72, 1999.
97. Sawyers CL. Chronic myeloid leukemia. *N Engl J Med* 340 (17): 1330-40, 1999.



98. Verfaillie CM. Biology of chronic myelogenous leukemia. *Hematol Oncol Clin North Am* 12 (1): 1-29, 1998.
99. Gordon MY, Dowding CR, Riley GP, *et al.* Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. *Nature* 328 (6128): 342-4, 1987.
100. Gishizky ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. *Science* 256 (5058): 836-9, 1992.
101. Fegan C, Morgan G, Whittaker JA. Spontaneous remission in a patient with chronic myeloid leukaemia. *Br J Haematol* 72 (4): 594-5, 1989.
102. Hasselbacher K, Wiggins RC, Matejas V, *et al.* Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. *Kidney Int* 70 (6): 1008-12, 2006.
103. Reese BE, Krissinger D, Yun JK, *et al.* Elucidation of stannin function using microarray analysis: implications for cell cycle control. *Gene Expr* 13 (1): 41-52, 2006.
104. Hagemeijer A, Smit EM, Lowenberg B, *et al.* Chronic myeloid leukemia with permanent disappearance of the Ph1 chromosome and development of new clonal subpopulations. *Blood* 53 (1): 1-14, 1979.
105. Sokal JE. Significance of Ph1-negative marrow cells in Ph1-positive chronic granulocytic leukemia. *Blood* 56 (6): 1072-6, 1980.
106. Smadja N, Krulik M, Audebert AA, *et al.* Spontaneous regression of cytogenetic and haematologic anomalies in Ph1-positive chronic myelogenous leukaemia. *Br J Haematol* 63 (2): 257-62, 1986.
107. Reiffers J, Broustet A, Goldman JM. Philadelphia chromosome-negative progenitors in chronic granulocytic leukemia. *N Engl J Med* 309 (23): 1460, 1983.
108. Coulombel L, Kalousek DK, Eaves CJ, *et al.* Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. *N Engl J Med* 308 (25): 1493-8, 1983.

109. Degliantoni G, Mangoni L, Rizzoli V. In vitro restoration of polyclonal hematopoiesis in a chronic myelogenous leukemia after in vitro treatment with 4-hydroperoxycyclophosphamide. *Blood* 65 (3): 753-7, 1985.
110. Barnett MJ, Eaves CJ, Phillips GL, *et al.* Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture. *Bone Marrow Transplant* 4 (4): 345-51, 1989.
111. Verfaillie CM, Miller WJ, Boylan K, *et al.* Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. *Blood* 79 (4): 1003-10, 1992.
112. Leemhuis T, Leibowitz D, Cox G, *et al.* Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. *Blood* 81 (3): 801-7, 1993.
113. Dunbar CE, Stewart FM. Separating the wheat from the chaff: selection of benign hematopoietic cells in chronic myeloid leukemia. *Blood* 79 (5): 1107-10, 1992.
114. Strife A, Clarkson B. Biology of chronic myelogenous leukemia: is discordant maturation the primary defect? *Semin Hematol* 25 (1): 1-19, 1988.
115. Meyerson HJ, Farhi DC, Rosenthal NS. Transient increase in blasts mimicking acute leukemia and progressing myelodysplasia in patients receiving growth factor. *Am J Clin Pathol* 109 (6): 675-81, 1998.
116. Spiers AS, Bain BJ, Turner JE. The peripheral blood in chronic granulocytic leukaemia. Study of 50 untreated Philadelphia-positive cases. *Scand J Haematol* 18 (1): 25-38, 1977.
117. Kantarjian HM, Giles FJ, O'Brien SM, *et al.* Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. *Hematol Oncol Clin North Am* 12 (1): 31-80, 1998.
118. Dickstein JI, Vardiman JW. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. *Am J Clin Pathol* 99 (4): 513-25, 1993.
119. Kantarjian HM, Dixon D, Keating MJ, *et al.* Characteristics of accelerated disease in chronic myelogenous leukemia. *Cancer* 61 (7): 1441-6, 1988.

120. Muehleck SD, McKenna RW, Arthur DC, *et al.* Transformation of chronic myelogenous leukemia: clinical, morphologic, and cytogenetic features. *Am J Clin Pathol* 82 (1): 1-14, 1984.
121. Rosenthal S, Canellos GP, DeVita VT, Jr., *et al.* Characteristics of blast crisis in chronic granulocytic leukemia. *Blood* 49 (5): 705-14, 1977.
122. Derderian PM, Kantarjian HM, Talpaz M, *et al.* Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. *Am J Med* 94 (1): 69-74, 1993.
123. Urbano-Ispizua A, Cervantes F, Matutes E, *et al.* Immunophenotypic characteristics of blast crisis of chronic myeloid leukaemia: correlations with clinico-biological features and survival. *Leukemia* 7 (9): 1349-54, 1993.
124. Cervantes F, Villamor N, Esteve J, *et al.* 'Lymphoid' blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. *Br J Haematol* 100 (1): 123-8, 1998.
125. Dorfman DM, Longtine JA, Fox EA, *et al.* T-cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings. *Am J Clin Pathol* 107 (2): 168-76, 1997.
126. Hastie ND. The genetics of Wilms' tumor--a case of disrupted development. *Annu Rev Genet* 28: 523-58, 1994.
127. Rauscher FJ, 3rd. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. *Faseb J* 7 (10): 896-903, 1993.
128. Haber DA, Sohn RL, Buckler AJ, *et al.* Alternative splicing and genomic structure of the Wilms tumor gene WT1. *Proc Natl Acad Sci U S A* 88 (21): 9618-22, 1991.
129. Sharma PM, Bowman M, Madden SL, *et al.* RNA editing in the Wilms' tumor susceptibility gene, WT1. *Genes Dev* 8 (6): 720-31, 1994.
130. Ehrnfelt C, He Z, Holgersson J. No role of alpha-Gal in human monocyte-endothelial cell interactions in vitro. *Scand J Immunol* 62 (5): 445-52, 2005.
131. Kent J, Coriat AM, Sharpe PT, *et al.* The evolution of WT1 sequence and expression pattern in the vertebrates. *Oncogene* 11 (9): 1781-92, 1995.

132. Kennedy D, Ramsdale T, Mattick J, *et al.* An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling. *Nat Genet* 12 (3): 329-31, 1996.
133. Caricasole A, Duarte A, Larsson SH, *et al.* RNA binding by the Wilms tumor suppressor zinc finger proteins. *Proc Natl Acad Sci U S A* 93 (15): 7562-6, 1996.
134. Davies RC, Calvio C, Bratt E, *et al.* WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. *Genes Dev* 12 (20): 3217-25, 1998.
135. Clugston RD, Klattig J, Englert C, *et al.* Teratogen-induced, dietary and genetic models of congenital diaphragmatic hernia share a common mechanism of pathogenesis. *Am J Pathol* 169 (5): 1541-9, 2006.
136. Larsson SH, Charlieu JP, Miyagawa K, *et al.* Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. *Cell* 81 (3): 391-401, 1995.
137. Renshaw J, King-Underwood L, Pritchard-Jones K. Differential splicing of exon 5 of the Wilms tumour (WT1) gene. *Genes Chromosomes Cancer* 19 (4): 256-66, 1997.
138. Mrowka C, Schedl A. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features. *J Am Soc Nephrol* 11 Suppl 16: S106-15, 2000.
139. Morris JF, Madden SL, Tournay OE, *et al.* Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus. *Oncogene* 6 (12): 2339-48, 1991.
140. Bruening W, Pelletier J. A non-AUG translational initiation event generates novel WT1 isoforms. *J Biol Chem* 271 (15): 8646-54, 1996.
141. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. *Gene* 273 (2): 141-61, 2001.
142. Bruening W, Moffett P, Chia S, *et al.* Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product. *FEBS Lett* 393 (1): 41-7, 1996.
143. Koesters R, Linnebacher M, Coy JF, *et al.* WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. *Int J Cancer* 109 (3): 385-92, 2004.

144. Loeb DM. WT1 influences apoptosis through transcriptional regulation of Bcl-2 family members. *Cell Cycle* 5 (12): 1249-53, 2006.
145. Oji Y, Suzuki T, Nakano Y, *et al.* Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. *Cancer Sci* 95 (10): 822-7, 2004.
146. Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. *Oncogene* 24 (9): 1648-52, 2005.
147. Oka Y, Tsuboi A, Taguchi T, *et al.* Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. *Proc Natl Acad Sci U S A* 101 (38): 13885-90, 2004.
148. Niksic M, Slight J, Sanford JR, *et al.* The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. *Hum Mol Genet* 13 (4): 463-71, 2004.
149. Gao F, Maiti S, Alam N, *et al.* The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis. *Proc Natl Acad Sci U S A* 103 (32): 11987-92, 2006.
150. Maretto S, Cordenonsi M, Dupont S, *et al.* Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. *Proc Natl Acad Sci U S A* 100 (6): 3299-304, 2003.
151. Kemler R, Hierholzer A, Kanzler B, *et al.* Stabilization of beta-catenin in the mouse zygote leads to premature epithelial-mesenchymal transition in the epiblast. *Development* 131 (23): 5817-24, 2004.
152. Liebner S, Cattelino A, Gallini R, *et al.* Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. *J Cell Biol* 166 (3): 359-67, 2004.
153. Jomgeow T, Oji Y, Tsuji N, *et al.* Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. *Cancer Sci* 97 (4): 259-70, 2006.
154. Maurer U, Brieger J, Weidmann E, *et al.* The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. *Exp Hematol* 25 (9): 945-50, 1997.


155. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. *Exp Hematol* 25 (4): 312-20, 1997.
156. Menssen HD, Renkl HJ, Rodeck U, *et al.* Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. *Leukemia* 9 (6): 1060-7, 1995.
157. Brieger J, Weidmann E, Fenchel K, *et al.* The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. *Leukemia* 8 (12): 2138-43, 1994.
158. Brieger J, Weidmann E, Maurer U, *et al.* The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. *Ann Oncol* 6 (8): 811-6, 1995.
159. Miyagawa K, Hayashi Y, Fukuda T, *et al.* Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. *Genes Chromosomes Cancer* 25 (2): 176-83, 1999.
160. Algar E, Blackburn D, Kromykh T, *et al.* Mutation analysis of the WT1 gene in sporadic childhood leukaemia. *Leukemia* 11 (1): 110-3, 1997.
161. Smith SI, Down M, Boyd AW, *et al.* Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice. *Cancer Res* 60 (4): 808-14, 2000.
162. Smith SI, Weil D, Johnson GR, *et al.* Expression of the Wilms' tumor suppressor gene, WT1, is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells. *Blood* 91 (3): 764-73, 1998.
163. Svedberg H, Chylicki K, Baldetorp B, *et al.* Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. *Oncogene* 16 (7): 925-32, 1998.
164. Inoue K, Tamaki H, Ogawa H, *et al.* Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. *Blood* 91 (8): 2969-76, 1998.
165. Deuel TF, Guan LS, Wang ZY. Wilms' tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain. *Biochem Biophys Res Commun* 254 (1): 192-6, 1999.

166. Tsuboi A, Oka Y, Ogawa H, *et al.* Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). *Leuk Res* 23 (5): 499-505, 1999.
167. Svedberg H, Richter J, Gullberg U. Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34(+) progenitor cells. *Leukemia* 15 (12): 1914-22, 2001.
168. Ellisen LW, Carlesso N, Cheng T, *et al.* The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. *Embo J* 20 (8): 1897-909, 2001.
169. Patmasiriwat P, Fraizer GC, Claxton D, *et al.* Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities. *Leukemia* 10 (7): 1127-33, 1996.
170. Pritchard-Jones K, Renshaw J, King-Underwood L. The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient. *Hum Mol Genet* 3 (9): 1633-7, 1994.
171. Bickmore WA, Oghene K, Little MH, *et al.* Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. *Science* 257 (5067): 235-7, 1992.
172. Jayaweera AR, Matthew TL, Sklenar J, *et al.* Method for the quantitation of myocardial perfusion during myocardial contrast two-dimensional echocardiography. *J Am Soc Echocardiogr* 3 (2): 91-8, 1990.
173. Quisumbing AR. Modeling household behavior in developing countries: discussion. *Am J Agric Econ* 78 (5): 1346-8, 1996.
174. Krajewski J, Dobecki M. [Determination of vinyl chloride in the air by the gas chromatography method]. *Med Pr* 29 (5): 403-10, 1978.
175. Ishimaru K, Nishikawa K, Omoto T, *et al.* Two flavone 2'-glucosides from *Scutellaria baicalensis*. *Phytochemistry* 40 (1): 279-81, 1995.
176. Nilar, Harrison LJ. Xanthenes from the heartwood of *Garcinia mangostana*. *Phytochemistry* 60 (5): 541-8, 2002.

177. Chairungrilerd N, Furukawa K, Ohta T, *et al.* Pharmacological properties of alpha-mangostin, a novel histamine H1 receptor antagonist. *Eur J Pharmacol* 314 (3): 351-6, 1996.
178. Jayawaeera. D.M.A. :Medicine Plants used in Ceylon Part 3. National Science Council of Sri Lanka. Comlumbo. 1981.
179. Quisumbing, Eduardo :Medicinal Plants of the Philipines. Katha Publishing Company. JMC PRESS. Quezon City. Philipines. 1978. ISBN No.
180. Krajewski, D; Toth, G; Schreier, P. 2 – Ethyl – 3 – methyleimide N – beta – D – glucopyranoside from the leaves of mangoteen (*Garcinia mangostana*). *Phytochemistry* (1996) 43(1): 141 – 143.
181. Asai F, Tosa H, Tanaka T, *et al.* Axanthon from pericaps of *Garcinia mangostana*. *Phytochemistry* (1995) 39(4): 943 – 944.
182. Nakatani K, Atsumi M, Arakawa T, *et al.* Inhibitions of histamine release and prostaglandin E2 synthesis by mangosteen, a Thai medicinal plant. *Biol Pharm Bull* 25 (9): 1137-41, 2002.
183. Chairungrilerd N, Takeuchi K, Ohizumi Y, *et al.* Mangostanol, a prenyl xanthon from *Garcinia mangostana*. *Phytochemistry* (1996) 43(5): 1099 – 1102.
184. Gopalakrishnan G, Banumathi B, Two novel xanthes from *Garcinia mangostana*. *Fitoterapia*. 2000 Sep; 71(5): 519 – 524.
185. Ho CK, Huang YL, Chen CC. Garcinone E, a xanthon derivative, has potent cytotoxic effect against hepatocellular carcinoma cell lines. *Planta Med* 68 (11): 975-9, 2002.
186. Moongkarndi P, Kosem N, Luanratana O, *et al.* Antiproliferative activity of Thai medicinal plant extracts on human breast adenocarcinoma cell line. *Fitoterapia* 75 (3-4): 375-7, 2004.
187. Moongkarndi P, Kosem N, Kaslungka S, *et al.* Antiproliferation, antioxidation and induction of apoptosis by *Garcinia mangostana* (mangosteen) on SKBR3 human breast cancer cell line. *J Ethnopharmacol* 90 (1): 161-6, 2004.
188. Chiang LC, Cheng HY, Chen CC, *et al.* In vitro anti-leukemic and antiviral activities of traditionally used medicinal plants in Taiwan. *Am J Chin Med* 32 (5): 695-704, 2004.



189. Anuchapreeda S, Tima S, Duangrat C, *et al.* Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines. *Cancer Chemother Pharmacol* 62 (4): 585-94, 2008.
190. <http://www.thaiherb.com/uploads/2007/12/mangosteen.jpg>
191. <http://www.dabbler.ca/wp-content/uploads/2008/05/molecule2.jpg>
192. <http://commons.wikimedia.org/wiki/File:Mangostin.png>



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright© by Chiang Mai University  
All rights reserved